Senseonics Holdings (SENS) Company Report

Senseonics Holdings, Inc. has received CE Mark approval for its Eversense® 365 Continuous Glucose Monitoring (CGM) system, enabling its commercialization in the European Union (EU).
The Eversense 365 is the world's first and only one-year CGM, which was previously approved by the US FDA in September 2024 and launched in the US in October 2024.
The company expects to launch Eversense 365 in Germany, Italy, Spain, and Sweden in the coming months, anticipating this expansion to contribute to top-line revenue growth and increase its total addressable market by over 30 million patients in the EU.
Senseonics is taking full ownership of all commercial activities for Eversense 365 and projects further commercial progress in the U.S. and Europe in 2026, alongside the integration with Sequel’s twiist™ Automated Insulin Delivery (AID) System and the planned completion of the Gemini trial.

Jan 29, 2026, 9:01 PM

Press Release

Veramatic Appoints New CEO

SENS

CEO Change

Management Change

Hiring

Veramatic (formerly Accumatic), an accounting control software company for dealerships, announced the appointment of George Sens as Chief Executive Officer, effective December 1, 2025.
Sens succeeds co-founder Tobey Bryant, who transitioned to Chair of the Board of Directors.
Sens brings deep auto-tech experience and a track record of scaling SaaS businesses to Veramatic.
Under Sens' leadership, Veramatic plans to accelerate penetration in franchise dealership groups and expand into new verticals like heavy trucking and RV within the next 12-24 months.

Jan 28, 2026, 12:00 PM

Press Release

Senseonics Announces Preliminary Unaudited Q4 and Full Year 2025 Revenue and Provides 2026 Guidance

SENS

Earnings

Guidance Update

Revenue Acceleration/Inflection

Senseonics reported preliminary unaudited revenue of approximately $14.2 million for Q4 2025, a 71% increase year-over-year, and approximately $35.2 million for full year 2025, a 57% increase year-over-year.
The company issued 2026 revenue guidance of $58-$62 million, representing a 65% to 76% increase over 2025 revenue, with an anticipated full-year gross margin of approximately 50%.
New patient growth in the U.S. increased by 103% in Q4 2025 compared to the same period in 2024, and Senseonics will assume commercialization and distribution of Eversense® from Ascensia Diabetes Care starting January 1, 2026.
The unaudited balance of cash, cash equivalents, and restricted cash as of December 31, 2025, is expected to be approximately $94.3 million.

Jan 12, 2026, 1:25 PM

8-K

Senseonics Announces Commercial Launch of Integrated Eversense 365 and twiist AID System

SENS

Product Launch

New Projects/Investments

Senseonics Holdings, Inc. and Sequel MedTech, LLC have launched the integration of their products, with the first patients having received a Sequel twiist AID system paired with the Eversense 365 Continuous Glucose Monitor (CGM).
This integration represents the first time the world's only One Year CGM system (Eversense 365) has been integrated with an Automated Insulin Delivery (AID) system, offering enhanced flexibility and personalization for people with type 1 diabetes.
The Eversense 365 is highlighted as the only implantable CGM available, providing one year of accurate monitoring with minimal interruptions.
Broad availability of twiist with Eversense 365 is expected by March 2026.

Jan 8, 2026, 9:01 PM

Press Release

Senseonics Holdings, Inc. Acquires Eversense U.S. Commercial Assets and Restructures European Rights

SENS

M&A

Board Change

New Projects/Investments

Senseonics Holdings, Inc. (SENS) acquired the U.S. commercial assets for its Eversense® product from Ascensia Diabetes Care Holdings AG for approximately $1.1 million, with the U.S. Asset Purchase closing on January 1, 2026.
Effective January 1, 2026, Senseonics, Inc. will be entitled to 100% of revenues from Eversense product sales in the European Territories, and the Seller's U.S. marketing rights have been terminated. The company also intends to acquire European commercial assets in Italy, Germany, Spain, and Sweden, with these closings expected on or before June 30, 2026.
Koichiro Sato resigned from the Board of Directors, effective December 31, 2025, in connection with these transactions.

Jan 2, 2026, 12:00 PM

8-K

Senseonics Holdings, Inc. Reports Q3 2025 Financial Results and Updates Outlook

SENS

Earnings

Guidance Update

Revenue Acceleration/Inflection

Senseonics Holdings, Inc. reported Q3 2025 revenue of $8.1 million, representing a 90% increase year-over-year, driven by a 160% rise in U.S. new patient starts.
The company's net loss for Q3 2025 was $19.5 million, or a $0.43 loss per share, an improvement from a $24.0 million net loss, or $0.77 loss per share, in Q3 2024.
Senseonics is planning to transition commercial responsibility for its Continuous Glucose Monitoring (CGM) products from Ascensia Diabetes Care back to Senseonics.
For the full year 2025, Senseonics anticipates global net revenue of approximately $35 million, with gross margins expected to be between 35% and 40%, and cash used in operations of approximately $60 million.
A 1-for-20 reverse stock split was executed on October 17, 2025, resulting in approximately 41 million outstanding shares, and the company plans to transfer its stock exchange listing to the Nasdaq Global Market on November 17th.

Nov 5, 2025, 9:15 PM

8-K

Senseonics Holdings Reports Q3 2025 Financial Results and Updates Full-Year Outlook

SENS

Earnings

Guidance Update

Delisting/Listing Issues

Senseonics Holdings reported Q3 2025 revenue of $8.1 million, a 90% year-over-year increase, primarily driven by a 160% increase in U.S. new patient starts.
The company's net loss improved to $19.5 million, or $0.43 per share, in Q3 2025, compared to a net loss of $24.0 million, or $0.77 per share, in Q3 2024.
Gross profit for Q3 2025 was $3.5 million, a significant improvement from a gross loss of $(4.1) million in Q3 2024.
Senseonics expects full-year 2025 global net revenue to be approximately $35 million, with gross margins between 35% and 40%.
The company is planning to transition CGM commercial responsibility back from Ascensia Diabetes Care, executed a 1-for-20 reverse stock split, and will transfer its stock exchange listing to the Nasdaq Global Market on November 17th.

Nov 5, 2025, 9:05 PM

Press Release

Senseonics Holdings, Inc. to Implement 1-for-20 Reverse Stock Split

SENS

Delisting/Listing Issues

Proxy Vote Outcomes

Senseonics Holdings, Inc. filed a Certificate of Amendment on October 16, 2025, to implement a one-for-twenty (1-for-20) reverse stock split of its common stock.
The reverse stock split will be effective at 4:05 p.m. Eastern Time on October 17, 2025, and the common stock is expected to begin trading on a split-adjusted basis on the NYSE American on October 20, 2025.
Concurrently, the total number of authorized common shares will be reduced from 1,400,000,000 to 70,000,000.
No fractional shares will be issued; instead, stockholders entitled to fractional shares will receive a cash payment.

Oct 16, 2025, 8:16 PM

8-K

Senseonics Reports Preliminary Q3 2025 Revenue and Announces Reverse Stock Split

SENS

Earnings

Revenue Acceleration/Inflection

Delisting/Listing Issues

Senseonics Holdings, Inc. reported preliminary unaudited revenue of $8.1 million for the third quarter of 2025, marking a 91% increase compared to Q3 2024.
This revenue growth was driven by approximately 160% new patient growth in the U.S. over the prior year, resulting in record quarterly new patient starts.
The company announced a one-for-twenty (1:20) reverse stock split, anticipated to be effective on October 17, 2025, with post-split trading commencing on October 20, 2025.
This reverse stock split will reduce the number of outstanding common shares from approximately 816 million to approximately 41 million.

Oct 6, 2025, 8:26 PM

8-K

Senseonics Announces Preliminary Q3 2025 Revenue and Reverse Stock Split

SENS

Revenue Acceleration/Inflection

Delisting/Listing Issues

Guidance Update

Senseonics reported preliminary unaudited revenue of $8.1 million for the third quarter of 2025.
This represents a 91% increase in revenue compared to the third quarter of 2024, primarily driven by approximately 160% new patient growth in the U.S..
The company will conduct a 1:20 reverse stock split, anticipated to be effective on October 17, 2025, with post-split trading beginning on October 20, 2025.
This reverse stock split will reduce the number of outstanding shares from approximately 816 million to 41 million.